THE EVOLUTION OF INFUSION THERAPY
IN POST-SURGICAL PAIN MANAGEMENT

Ropivacaine
ReadyfusOR

BioQ Pharma
Enhanced safety and sterility in post-operative pain management.
> Pre-filled reservoir at manufacturing site requires no manual preparation steps where error can be introduced or sterility can be compromised.
> Proprietary design precludes the risk of overdosing due to delivery malfunction.
> Single patient and single use.
> Disposable following use.
> Convenient and easy to use.
> Self-contained and ready to use at the point-of-care.
> Pre-prepared and requires no measuring, mixing or external drug transfer.
> Activated in one simple touch.

Fast effective pain control.
> Contains the active agent, Ropivacaine, a pharmaceutical with a trusted efficacy and safety profile established through decades of clinical use.
> Treats pain locally via continuous wound infusion or continuous peripheral nerve block, reducing the need for opioids.
> An advanced infusion system delivering 250 ml ropivacaine 0.2% at a constant flow rate of 5 ml/hour, providing at least 48 hours postoperative pain control.
> Provides premium patient comfort through early mobility.

Enhanced safety and sterility in post-operative pain management.
> Pre-filled reservoir at manufacturing site requires no manual preparation steps where error can be introduced or sterility can be compromised.
> Proprietary design precludes the risk of overdosing due to delivery malfunction.
> Single patient and single use.
> Disposable following use.

Why should I use Ropivacaine ReadyfusOR?
The continuous infusion of 0.2% ropivacaine has been shown to reduce pain scores, and to promote early patient mobility. A continuous infusion of ropivacaine 0.2% has also been shown to be opioid sparing and to reduce opioid-related side effects such as respiratory depression, abnormal bowel function, and postoperative nausea and vomiting.

Convenient and easy to use.
> Self-contained and ready to use at the point-of-care.
> Pre-prepared and requires no measuring, mixing or external drug transfer.
> Activated in one simple touch.
> Convenient for professionals and patients.
> Unit dose for a single patient.
> Wearable and portable.
> Disposable following use.

Lower cost of drug delivery
> Reduces pharmacy and nursing time.
> Eliminates time spent preparing infusion and setting up pump.
> Limits risk for product expiration and waste.

Minimize cost of avoidable drug complications
> Pre-filled and ready-to-use to minimize medication errors.
> Sterility ensured to reduce the risk of hospital-acquired infections.
> One-touch activation with no manipulation of flow rate eliminates incorrect programming of pump.

Support for early mobility and reduced hospital length of stay
> Enhances patient recovery.
> Promotes faster ambulation and healing.
> Potential to reduce the total cost of care.

What is the best way to treat post-surgical pain?
Successfully managing post-surgical pain and maintaining a constant level of analgesia is critical to a patient’s recovery. A continuous infusion of a local anesthetic for the first 48 hours post-operatively provides a constant flow of medication to the affected area, preventing gaps in treatment often seen with other pain management methods.

What is Ropivacaine ReadyfusOR?
Ropivacaine ReadyfusOR is a self-contained infusion system pre-filled at the manufacturing site with 250 ml ropivacaine 0.2%. Once activated by a single touch, Ropivacaine ReadyfusOR delivers a continuous infusion at a constant flow rate of 5 ml per hour, and is intended to provide premium pain control.

ROPIVACAINE READYFUSOR
EFFECTIVE – SAFE – SIMPLE
REDEFINING THE STANDARDS OF TREATING POST-SURGICAL PAIN
The infusion system is activated with one touch by simply rotating the cap to the “on” position and connecting to the infusion catheter.

- Prefilled ready-to-use infusion system for single use per patient. Cannot be refilled, decreasing the risk for human error or infection.
- Infusion system prefilled at the manufacturer with 0.2% ropivacaine.
- Ergonomic design and carrying case allow for patient mobility and ambulation aiding in faster recovery times.
- Proprietary design makes medication “free flow” impossible.
- Flow rate accuracy should prevent over/under dosing.

WHY PRESCRIBE:

Ropivacaine ReadyfusOR is intended to provide long-lasting, non-narcotic pain control for more than 48 hours and it therefore should enable premium patient comfort.

- Improves pain control during the acute phase post-operatively.
- Faster mobility and return to normal function.
- Reduces consumption of narcotic / opiate sparing.
- Reduces post-operative nausea and vomiting.
- Reduces risk for contamination and infection thanks to no manipulation of active drug ingredient, vials and lines.
- May contribute to a reduced length of hospital stay for the patient.

WHEN TO PRESCRIBE:

Ropivacaine ReadyfusOR should be prescribed:

- Post-surgically for medically appropriate procedures* that require at least 48 hours of pain relief.
- When patients require effective pain control without gaps in treatment or harsh side effects.

Please see full prescribing information for Ropivacaine ReadyfusOR.
Ropivacaine can be administered to most parts of the body through continuous local infusions or continuous peripheral nerve blocks. Delivery of ropivacaine through a catheter has shown to be an effective technique for controlling postoperative pain. With continuous infusion of ropivacaine, only the local or regional area is affected by the medication.

Continuous Wound Site Infusion
A fenestrated (multi-holed) catheter may be inserted into the surgical site to distribute the 0.2% ropivacaine inside the wound and provide premium postoperative pain control.

Continuous Peripheral Nerve Block
A catheter is inserted percutaneously adjacent to the peripheral nerve that is most relevant to the surgical site, thereby providing sensory and motor analgesia.
About BioQ Pharma

BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company’s infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma’s vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company’s proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma’s commercial collaborators and strategic partners include Novartis’ Sandoz unit, Cipla, Lee’s Pharm, Lunatus, and West Pharmaceutical Services.

BioQ Pharma Incorporated
185 Berry Street, Suite 160
San Francisco, CA 94107
U.S.A.

BioQ Pharma B.V.
Amelia Earhartlaan 17
9051 Sint-Denijs-Westrem
Belgium

www.bioqpharma.com